PasNas, the ABAC Therapeutics‘ Technology Platform
PasNas is the drug discovery platform engineered and exploited by ABAC Therapeutics. It is a highly scalable and multiplex platform capable of effectively unveiling pathogen-specific antibacterial properties of molecules, while promoting the compounds active against MDR strains with new mechanism of action and with maximized chances of success in clinical development.
PasNas platform has been validated and shows remarkable results. The successful application of the PasNas Platform has enabled ABAC Therapeutics to discover novel compounds active against the “Big Four” Gram-negative bacteria, one series of which has pathogen-specific activity against Acinetobacter baumannii in late lead optimization and to progress pathogen-specific antibacterial lead compounds active against Escherichia coli and Klebsiella pneumoniae into chemical optimization (ABAC’s pipeline).